📢No difference in ESRD or mortality with RTX-based vs CYC-based induction regimen in ANCA #Vasculitis #ACR21 https://t.co/Bdz5t2uyHi

#ACR21 #ACR2021 Clinical Pearls 🚨 Thread Alert 1/n 💥AAV does not typically cause hard palate lesions➡️consider: Cocaine induced midline destructive lesion(HNE+)/Malignancy 💥Limited GPA can be ANCA negetive in 50% 💥 oral cavity examination is a must in Rheum https://t.co/RxkLiGdcJt

#ACR21 TM24. Hydralazine-induced ANCA vasculitis presenting with chondritis. Labs: +ANA +Anti-histone +p-ANCA, +MPO and +PR3 @Rheumnow https://t.co/YQvqj0vCHp https://t.co/LPyVYYzLtI

• https://bit.ly/3F2fNGm

#ACR21 2022 ACR/EULAR GPA Criteria ▶️Classification, NOT diagnostic! ⭐️Clinical, lab, imaging, and biopsy criteria ⭐️+5 pts for cANCA or PR3, negative pts for pANCA or MPO, or eosinophilia @RheumNow https://t.co/6YWmabNzuH https://t.co/vg8zaFt5dR

• https://bit.ly/3o7N9gi

ACR/EULAR Classification Criteria for ANCA vasculitis, updated from prior Similar disclaimer; these are for use AFTER the diagnosis of small or medium vasculitis has been made Great international effort, kudos to all involved #ACR21 #ACRambassador https://t.co/a29TVvzVF7

#ACR21 new 2022 classification criteria by ACR/EULAR for AAV 💥GPA-Sensitivity-92%, Specificity-94% 💥MPA-Sensitivity-91%, Specificity-94% 💥EGPA-Sensitivity-85%, Specificity-99% 💥Score based https://t.co/61SOl4Tovg

What's Cool and Hot in Vasculitis: Dr. Janet Pope reviews abstracts #0505, #0466, #0430, #0507 and #0504, being presented at the #ACR21 annual meeting. https://t.co/7XwjFuJEMM https://t.co/BC9wjPzNC0

• https://bit.ly/3kjes6i

#ACR21 2022 ACR/EULAR MPA Criteria ▶️Classification, NOT diagnostic! ⭐️Clinical: negative for nasal GPA symptoms ⭐️Lab: +6 for pANCA or MPO, negative for cANCA/PR3 or eosinophilia @RheumNow https://t.co/6YWmabNzuH https://t.co/XVzBF2KONp

• https://bit.ly/3o7N9gi

#ACR21 2022 ACR/EULAR Large Vessel Vasculitis Criteria: 🌎One reason for updating 31 year old criteria -> now an international effort that better reflects heterogeneous global disease @RheumNow https://t.co/6YWmabNzuH https://t.co/YXm85uQZCK

• https://bit.ly/3o7N9gi

ACR/EULAR Classification Criteria for Large Vessel Vasculitis (TAK/GCA), updated from prior to include imaging Must emphasize typical disclaimers; these are for classification, not specifically for diagnosis Great effort and useful result, esp for trials #ACR21 @petercgrayson https://t.co/IYFyh5oYBT

#ACR21 2022 ACR/EULAR GCA Criteria ▶️Classification, NOT diagnostic! ⭐️Must be >50yo ⭐️Clinical, lab, imaging, and biopsy findings +TA biopsy or Halo sign = 5 points, 6+ points needed for classification @RheumNow https://t.co/6YWmabNzuH https://t.co/cZVrWA02U6

• https://bit.ly/3o7N9gi

#ACR21 #AbstrL21 Phase III RCT which stratified pts using FFS showed no superiority of Rituximab vs SOC for remission induction of EGPA #vasculitis at Day 180 (63.5% vs 60.4%). No difference in secondary endpoints, safety or subgroup analyses @RheumNow https://t.co/AbdAvlU0Bg https://t.co/yta1CM7hrs

• Rituximab versus Conventional Therapeutic Strategy for Remission Induction in E…

IL17 IS Impt in giant cell arthritis. Who would’ve thought that #secukinumab would treat #GCA? More options for pts. Only 52 pts but maybe another Rx for GCA? #ACR21 abst#L19 https://t.co/dwbPmGswQ9